Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants

Pediatrics

Volumn 97, Issue 1, 1996, Pages 59-64

  Thea, Donald M ^a,h   Lambert, Genevieve ^b   Weedon, Jeremy ^a   Matheson, Pamela B ^a   Abrams, Elaine J ^c   Bamji, Mahrukh ^d   Straus, Walter L ^e   Thomas, Pauline A ^f   Krasinski, Keith ^g   Heagarty, Margaret ^c  

^a Medical and Health Research Association   (United States)

^b BRONX LEBANON HOSPITAL CENTER   (United States)

^c HARLEM HOSPITAL CENTER   (United States)

^d METROPOLITAN HOSPITAL CENTER   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f New York City Department of Health

^g BELLEVUE HOSPITAL CENTER   (United States)

^h Box 044   (United States)

Author keywords

pediatric acquired immunodeficiency syndrome; perinatal human immunodeficiency virus infection; Pneumocystis carinii pneumonia; primary prophylaxis; trimethoprimsulfamethoxazole

Indexed keywords

CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN; PENTAMIDINE; ZIDOVUDINE;

ARTICLE; CHILD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; INFECTION PREVENTION; INHALATIONAL DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MORTALITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGE FACTORS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; PNEUMONIA, PNEUMOCYSTIS; PREGNANCY; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 13344270385     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Caldwell B, Rogers M. Epidemiology of pediatric HIV infection. Pediatr Clin North Am. 1991;38:1-16
2. Davis S, Gwinn M, Wasser S, Fleming P, Karon J HIV prevalence among US childbearing women. Presented at the First National Conference on Human Retroviruses and Related Infections; December 12-16, 1993; Washington, DC. Abstract 10-27
3. Matheson PB, Weedon J, Capelli M, et al. Comparative methods of estimating mother-to-child HIV-1 transmission rate (MTCTR). Presented at the IXth International Conference on AIDS; June 6-11, 1993; Berlin, Germany. Abstract PO-C16-2948
4. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with the human immunodeficiency virus. MMWR. 1991,40(RR-2):1-13
5. Hughes W. Pneumocystis carinii pneumonia: new approaches to diagnosis, treatment and prevention. Pediatr Infect Dis J. 1991;10:391-399
6. Simonds RJ, Oxtoby MJ, Caldwell B, Gwinn ML, Rogers MF. Pneumocystis carinu pneumonia among US children with perinatally acquired HIV infection. JAMA. 1993,270:470-473
7. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethroprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185-1189
8. Hughes WT, Kuhn S, Choudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297: 1419-1426
9. Rutstein R. Predicting risk of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children. Am J Dis Child. 1991;145: 922-924
10. Connor E, Bagavazz M, McSherry G, et al. Clinical and laboratory correlates of Pneumocystis carinii pneumonia in children infected with HIV. JAMA. 1991;265:1693-1697
11. Centers for Disease Control. Classification system for human immunodeficiency virus infection in children under 13 years of age. MMWR. 1987;36:225-236
12. Rigaud M, Pollack H, Leibovitz, et al. Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. J Pediatr 1994;125:476-480
13. Centers for Disease Control. Interpretation and use of Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infection. MMWR. 1989;38:1-7
14. Rogers MF, Ou C-Y, Rayfield M, et al Use of polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. N Engl J Med. 1989;320:1649-1654
15. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis N Engl J Med. 1977;297 1419-1426
16. Hughes WT, Rivera GK, Schell MJ, Thorton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627-1632
17. Sanders-Laufer D, DeBruin W, Edelson P. Pneumocystis carinii infections in HIV-infected children. Pediatr Clin North Am. 1991,38:69-88
18. European Collaborative Study Group CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. Br Med J. 1994;308:437-440
19. Blanche S, Mayaux MJ, Rouzioux C, et al. Relation of the course of HIV infection in children to the severity of the disease in their mothers at delivery. N Engl J Med. 1994;30:308-312
20. Thomas PA, Weedon J, Krasinski K, et al. Maternal predictors of perinatal HIV transmission. Pediatr Infect Dis J. 1994;13:489-495
21. 9/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. JAMA. 1992;268:483-488
22. Frederick T, Mascola L, Eller A, Jackson J, Caldwell B, The Los Angeles Pediatric AIDS Consortium. Pneumocystis carinii pneumonia among perinatally HIV-infected children in Los Angeles County: are cases being prevented? Presented at the First National Conference on Human Retroviruses and Related Infections; December 12-16, 1993; Washington, DC. 1994:693. Abstract
23. Kovacs JA, Kovacs AAS. PCP prophylaxis in paediatric HIV infection: time for a change? Lancet 1994;344:5-6
24. de Martino M, Tovo P, Galli L, et al. Prognostic significance of immunologic changes in 675 infants perinatally exposed to human immunodeficiency virus. J Pediatr. 1991;119:702-709
25. McSherry G, Wright M, Oleske J, et al. Frequency of serious adverse reactions to trimethoprim-sulfamethoxazole and pentamidine among children with human immunodeficiency virus 1 infection. Presented at the 27th International Conference on Antimicrobial Agents and Chemotherapy, 1988; Los Angeles, CA. Abstract 1357
26. Asmar BI, Maqbool S, Dajani AS. Hematologic abnormalities after oral trimethoprim-sulfamethoxazole therapy in children. Am J Dis Child. 1980;135:1100-1103
27. Lawsen DH, Paice BJ. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients Clin Infect Dis. 1982;4:426-428
28. Obiri G, Thomas P, Caldwell B. Trends in and factors associated with age of the first medical evaluation for HIV infection among children born to HIV infected mothers in New York City (NYC). Presented at the II International Conference on HIV in Children and Mothers; September 7-10, 1993, Edinburgh, UK. Abstract P4.2
29. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43:285-288